Mycophenolate mofetil is approved by the US Food and Drug Administration for the treatment of renal allograft rejection, and recently it has received attention as an alternative steroid-sparing agent in dermatology.1-3 Dose-dependent nausea, vomiting, diarrhea, and abdominal pain are the most commonly encountered adverse effects. Bone marrow suppression and increased risk of infection are the major safety risks, and mycophenolate mofetil is generally thought to be free of hepatotoxic effects. Herein, we describe 2 patients with atopic dermatitis who developed increased levels of serum hepatic transaminases (liver function tests) following an increase in dosage of mycophenolate mofetil.
Hantash B, Fiorentino D. Liver Enzyme Abnormalities in Patients With Atopic Dermatitis Treated With Mycophenolate Mofetil. Arch Dermatol. 2006;142(1):109–116. doi:10.1001/archderm.142.1.109
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: